The efficacy of vaginal clindamycin for the treatment of abnormal genital tract flora in pregnancy

Infectious Diseases in Obstetrics and Gynecology

Volumn 11, Issue 4, 2003, Pages 181-189

  Lamont, Ronald F ^a,e,f   Jones, Brian M ^b   Mandal, Debashis ^c   Hay, Philip E ^d   Sheehan, Marie ^e  

^a EALING HOSPITAL NHS TRUST   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^d ST GEORGE S HOSPITAL   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f St Marks and Northwick Park Hospitals Harrow   (United Kingdom)

Author keywords

Bacterial vaginosis; Clindamycin; Efficacy; Pregnancy

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL FLORA; BACTERIAL INFECTION; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEMALE GENITAL TRACT INFECTION; GRAM STAINING; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREGNANCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; VAGINA SECRETION; VAGINITIS;

ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ADULT; CHI-SQUARE DISTRIBUTION; CLINDAMYCIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PROBABILITY; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK ASSESSMENT; TREATMENT OUTCOME; VAGINAL CREAMS, FOAMS, AND JELLIES; VAGINAL SMEARS; VAGINOSIS, BACTERIAL;

EID: 0345872356     PISSN: 10647449     EISSN: None     Source Type: Journal    
DOI: 10.1080/10647440300025519     Document Type: Article

References (31)

1. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram-stain interpretation. J Clin Microbiol 1991;29:297-301
2. Hay PE, Taylor-Robinson D, Lamont RF. Diagnosis of bacterial vaginosis in a gynaecology clinic. Br J Obstet Gynaecol 1992;99:63-6
3. Amsel R, Totten PA, Spiegel CA, et al. Non-specific vaginitis. Diagnostic criteria and microbial and epidemiological associations. Am J Med 1993;74:14-22
4. Geary M, Lamont RF. Prediction of preterm birth. In Elder MG, Lamont RF, Romero R, eds. Preterm Labor. New York: Churchill Livingston, 51-63
5. Sexually transmitted disease treatment guidelines 2002. Centers for Disease Control and Prevention. Recomm Rep 2002 May 10;51:(No RR-6)1-78
6. Thomason JL, Gelbart SM, Anderson RJ, et al. Statistical evaluation of diagnostic criteria for bacterial vaginosis. Am J Obstet Gynecol 1990;162:155-60
7. Lamont RF, Duncan SLB, Mandal D, Bassett P. Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora. Obstet Gynecol 2003;101:516-22
8. Livengood CH, Thomason JL, Hill GB. Bacterial vaginosis: diagnostic and pathogenic findings during topical clindamycin therapy. Am J Obstet Gynecol 1990;163:515-21
9. Hillier S, Krohn MA, Watts DH, et al. Microbiologic efficacy of intravaginal clindamycin cream for the treatment of bacterial vaginosis. Obstet Gynecol 1990;76:407-13
10. Borin MT, Powley GW, Tackwell KR, Batts DH. Absorption of clindamycin in bacterial vaginosis patients after intravaginal application of clindamycin phosphate 2% cream. Clin Pharmacol Ther 1992;51:185
11. Powley GW, Timm JA, Le VH. Clindamycin vaginal cream versus placebo vaginal cream for bacterial vaginosis during pregnancy. (Protocol M/1115/0006). Upjohn Technical Report 9156-92-019 December 1992. (Held on file Pharmacia and Upjohn, Kalamazoo, USA)
12. Powley GW, Timm JA, Greenwald CA. Comparison of two dosing regimens of 2% clindamycin vaginal cream for the treatment of bacterial vaginosis - 3 days versus 7 days. (Protocol M/1115/0020). Upjohn Technical Report 9156-93-006 December 1993. (Held on file at Pharmacia and Upjohn, Kalamazoo, USA)
13. Ahmed-Jusuf IH, Shahmanesh M, Arya OP. The treatment of bacterial vaginosis with a three day course of 2% clindamycin cream: results of a multicentre, double blind, placebo controlled trial. Genitourin Med 1995;71:254-6
14. Lamont RF. Bacterial vaginosis. In Studd JWW, Jardine-Brown C, eds. The Yearbook of the RCOG, London: Parthenon Publishing, 1995:149-60
15. Kent HL. Epidemiology vaginitis. Am J Obstet Gynecol 1991;165:1168-76
16. Hay PE, Lamont RF, Taylor-Robinson D, et al. Abnormal bacterial colonisation of the genital tract as a marker for subsequent preterm delivery and late miscarriage. Br J Med 1994;308:295-8
17. Newton ER, Prihoda TK, Gibbs RS. A clinical and microbiologic analysis of risk factors for puerperal endometritis. Obstet Gynecol 1990;75:402-6
18. Gibbs RS. Chorioamnionitis and bacterial vaginosis. Am J Obstet Gynecol 1993;169:460-2
19. Chin BM, Lamont RF. The microbiology of preterm labor and delivery. Cont Rev Obstet Gynecol 1997;9:285-96
20. Kurki T, Sivonen A, Renkonen OV, et al. Bacterial vaginosis in early pregnancy and pregnancy outcome. Obstet Gynecol 1992;80:173-7
21. Riduan JM, Hillier SL, Utomo B, et al. BV and prematurity in Indonesia: association in early and late pregnancy. Am J Obstet Gynecol 1993;169:175-8
22. Llahi-Camp JM, Rai R, Ison C, et al. Association of bacterial vaginosis with a history of second trimester miscarriage. Hum Reprod 1996;11:11575-8
23. McGregor JA, French JI, Jones W, et al. Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream. Am J Obstet Gynecol 1994;170:1048-60
24. Rosenstein IJ, Morgan DJ, Sheehan M, et al. Bacterial vaginosis in pregnancy: distribution of bacterial species in different gram-stain categories of the vaginal flora. J Med Microbiol 1996;45:120-6
25. Rosenstein IJ, Morgan DJ, Lamont RF, et al. Effect of vaginally applied clindamycin on vaginal microbial flora and outcome of pregnancy in women with bacterial vaginosis. Infect Dis Obstet Gynecol 2000;8:158-65
26. Joesoef MR, Hillier SL, Wiknjosastro G, et al. Intravaginal clindamycin treatment for bacterial vaginosis: effects on preterm delivery and low birth weight. Am J Obstet Gynecol 1995;173:1527-31
27. Vermeulen GM, Bruinse HW. Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomized placebo controlled double blind trial. Br J Obstet Gynaecol 1999;100:652-7
28. Lamont RF. Antibiotics for the prevention of preterm birth. N Engl J Med 2000;342:581-3
29. Mason MR, Adinkra PE, Lamont RF. Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased risk: a randomized placebo controlled double blind trial. Br J Obstet Gynaecol 2000;170:295-6;letter
30. Vermeulen GM. Changes in vaginal flora after 2% clindamycin vaginal cream in women at high risk of preterm birth. Br J Obstet Gynaecol 2001;108:697-700
31. Lamont RF. Changes in vaginal flora after 2% clindamycin vaginal cream in women at high risk of preterm birth. Br J Obstet Gynaecol (in press)